- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
Over 2,000 real rulings — analysed for what they mean to your team. Published every day.
Showing 1914 cases
Anonymous pharmacist alleged off-licence CKD promotion of Invokana at a diabetes conference. Panel couldn’t prove what was said (no breach), but ruled…
A UK-circulated press release about investigational ASTX727 made unsubstantiated benefit/safety claims and implied an incorrect indication for decitabine. Breaches: 3.1, 3.2, 7.9,…
Two online press releases about investigational ASTX727 were circulated to UK outlets. Panel found misleading, unsubstantiated study claims and failure to maintain…
Anonymous group alleged a third-party therapy review provider’s internal email showed commercial bias and disguised promotion in Amgen-funded osteoporosis reviews. Panel and…
A BMJ-hosted ad described Takhzyro as “a new preventative treatment”. PMCPA ruled Takhzyro had been promoted from 1 April 2019, so “new”…
A UK health professional alleged RoActemra prescribing information in a Guidelines in Practice product review was out of date vs SPC updates.…
A patient-organisation congress website listed Daiichi-Sankyo symposia agendas naming Lixiana, Nilemdo and Nustendi with indications but omitted mandatory prescribing/AE/black triangle info and…
Sanofi self-reported that a downloadable NICE technology appraisal resource on dupixent.co.uk for HCPs was live without certification during a system transition. PMCPA…
Camurus-funded Buvidal “clinical guidelines” and webinars were ruled promotional, lacked PI/AE reporting and INN, were not certified, and one webinar was publicly…
Leo Pharma UK admitted six promotional emails for Innohep were sent with broken single-click prescribing information links after a website merge. PMCPA…
PMCPA ruled Novartis’ edited Beovu “first experience” HCP video was misleading because it retained positive case outcomes but omitted the presenter’s caution…
Leo’s UK homepage lacked signposting to clinical trial results and it disclosed 2019 patient organisation support over 5 months late. Breaches of…
PMCPA found breaches where Nilemdo/Nustendi web claims implied add-on use with any lipid-lowering therapy, while key contraindications/caveats (eg simvastatin >40mg; bile acid…
A Guardian article quoted a Small Pharma employee making strong, unqualified claims about DMT ‘undoing’ depressive thoughts. The Panel found the claim…
A Nilemdo/Nustendi journal ad implied add-on use without clearly flagging simvastatin >40mg contraindication. PMCPA found the claim misleading with potential patient safety…
Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases — ask about precedents, clauses, and how they apply to your situation.
One real case. One key lesson. Every week — free.